Evaluation of concurrent and adjuvant carboplatin with radiation therapy for locally advanced cervical cancer

Comparison of Carboplatin- and Cisplatin-Based Concurrent Chemoradiotherapy in Locally Advanced Cervical Cancer Patients With Morbidity Risks

“…As expected with carboplatin, thrombocytopenia was more common in the CarboRT group, although the difference was not statistically significant (p ϭ .24). Specifically, grade 3-4 thrombocytopenia was noted in five patients (9.8%); this rate is higher than those reported in previous studies (range: 0%-6.4%) [11][12][13][14]16]. We speculated that the rate of thrombocytopenia was relatively higher because our patients had morbidity risks.…”

“…Compared with cisplatin, carboplatin is now used as an effective treatment regimen with an improved toxicity profile in ovarian cancer patients [10]. Despite this evidence, only a few small clinical trials of carboplatin-based chemoradiotherapy (CarboRT) in cervical cancer patients have been reported [11][12][13][14][15]. To our knowledge, there have been no reports comparing CarboRT with CisRT.…”

Surgery and radiotherapy in vulvar cancer

“…Carboplatin is a platinum analogue with similar properties but with less renal-, oto-, or neurotoxicity [148]. Carboplatin concurrent with radiotherapy has shown promising results in several uncontrolled trials [149][150][151][152][153][154]. Oral fluoropyramidines, because of their ease of administration, constitute an attractive alternative for fluorouracil.…”